Baker Bros. Advisors 13F: Adds $32M to ELVN Stake

Baker Bros. Advisors Multiplies Enliven Position

Health-focused investment firm Baker Bros. Advisors significantly increased its bet on Enliven Therapeutics, Inc. (NASDAQ: ELVN). According to its latest Form 13F filing with the SEC, the firm boosted its holdings in the clinical-stage biotechnology company by 233.5% during the reporting period ending May 15, 2026. This backward-looking filing reflects the fund's holdings as of that date and may not represent its current portfolio.

The fund added 633,785 shares of the oncology-focused developer, bringing its total position to 905,191 shares. The newly expanded stake is valued at approximately $45.94 million, based on a cost basis of $24.93 per share. This is a substantial step up from the 271,406 shares the fund held at the start of the period.

Enliven Stock Outperforms Moving Averages

Enliven Therapeutics shares closed at $50.75 on Sunday, trading comfortably above its 200-day moving average of $39.22. Despite some consolidation below its 50-day moving average of $56.22, the stock has carved out a massive recovery from its 52-week low of $14.78. The company has a market cap of approximately $3.58 billion. Because Enliven is still in its clinical development phase and does not yet have regular product revenue, it reports negative earnings per share of -$1.65 and has no meaningful price-to-earnings ratio.

Clinical Pipeline Drives Analyst Optimism

Wall Street analysts have maintained a highly optimistic outlook on Enliven's small-molecule cancer pipeline. On October 2, 2026, Morgan Stanley initiated coverage on the stock with an Overweight rating and a $70.00 price target. This followed JP Morgan initiating coverage on October 1, 2026, with an Overweight rating and a $75.00 price target.

Earlier in the summer, on August 18, 2026, Barclays initiated coverage with an Overweight rating and a $78.00 price target, while William Blair initiated an Outperform rating. On that same day, Mizuho maintained its Outperform rating and lifted its price target to $73.00 from $62.00. Earlier in August, Stifel, Guggenheim, and Goldman Sachs all maintained buy-equivalent ratings, with Goldman Sachs raising its target to $80.00 and Stifel adjusting its target to $82.00. Ten analysts tracking the stock maintain a consensus strong buy rating, with a mean price target of $73.90.

Focus on Small Molecule Cancer Inhibitors

Enliven Therapeutics is a clinical-stage biopharmaceutical company that develops targeted therapies for cancer patients. Its current efforts focus on two key programs in Phase 1 trials: ELVN-001, which targets chronic myeloid leukemia, and ELVN-002, designed to treat HER2-mutant lung cancers and other tumors. Large institutional backings, such as this expanded position from Baker Bros., help support the capital-intensive research and development required to push these candidates through clinical trials.

What to Watch at Enliven Therapeutics, Inc.

Investors tracking Enliven's progress should look forward to its next quarterly earnings report, scheduled for November 11, 2026. Because 13F filings are delayed by up to 45 days after the end of a calendar quarter, future regulatory filings will reveal whether Baker Bros. Advisors has continued to accumulate shares or if other institutional biotech specialists have followed their lead.